Common Labeling Deficiencies and Tips for Generic Drug Applications

Panel Discussion on Product-Specific Guidances

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Regulatory Education for Industry (REdI) – Devices and Biologics Track

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Roundtable on PMTA Submissions for ENDS Products

FDA’s Labeling Resources for Human Prescription Drugs

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions